The Lateral Cheek Is Not an Empty Space: Why Biostimulator Trends Need Restraint
- Dr. Lazuk
- 10 minutes ago
- 4 min read
An early PDLLA case series suggests that a protocol targeting the lateral cheek may improve appearance with high short-term satisfaction. It does not establish a universal cheek recipe. The study included 24 people, no comparison group, three sessions, and three-month outcomes. I see it as a signal worth watching—not permission to treat every flat, tired, or aging cheek with the same product and pattern.
The lateral cheek looks like open real estate on a diagram. In a face, it is part of a moving system.
What did the new PDLLA study show?
The 2026 case series followed 24 participants who received three sessions at three-week intervals. Investigators reported aesthetic improvement and high satisfaction. Bruising was transient, and no serious adverse events were reported during the short follow-up.
Those results are encouraging. The study was uncontrolled, outcomes included subjective measures, and follow-up was limited. Without a comparator, we cannot know how much change came from the protocol, measurement conditions, natural variation, or expectation. We also cannot infer long-term maintenance or delayed-event rates from 24 people.
Why does cheek anatomy change the answer?
Cheek appearance can reflect bone structure, fat-compartment position, ligament support, skin quality, muscle activity, prior filler, swelling, and overall facial proportion. Adding a collagen-stimulating product to the wrong layer or the wrong problem can create heaviness without restoring harmony.
That is why I do not treat “volume loss” as a single diagnosis. A narrow face may need support; a heavy midface may need restraint. A person may need skin-quality work, structural filler, no injectable, or a surgical opinion. The same photograph can suggest different plans when examined in motion.
For a broader view of how I separate goals and layers, read my approach to individualized planning. Readers comparing injectable categories can use the Injectables Explorer as education before a consultation.
What makes a biostimulator decision different from filler?
Some biostimulatory products produce gradual tissue response rather than an immediately editable gel result. That affects reversibility, patience, and correction strategy. Product identity, regulatory status, preparation, injection technique, and approved use vary. “PDLLA” should not be used as a generic promise for all collagen stimulators.
Treatment math also matters. Three sessions at three-week intervals are a commitment, not a single appointment. The person should understand the time to visible change, maintenance uncertainty, cost factors, and what happens if the result is subtler—or fuller—than expected.
When would I not recommend this trend?
I would not recommend chasing a protocol because it is new, treating without verifying the exact product, or using an early case series as proof of superiority. I would hesitate when prior filler is poorly documented, swelling is unexplained, facial heaviness is already a concern, or the person expects instant and precisely reversible correction.
I would also recommend no treatment when the lateral cheek is not the true source of the concern. A camera angle, weight change, lighting, or temporary fatigue can turn normal anatomy into a perceived defect.
What would make the evidence stronger?
Larger controlled studies, more diverse participants, standardized objective measurements, longer follow-up, transparent adverse-event reporting, and comparison with established options would all change my confidence. Product-specific evidence is essential; a result should not be borrowed by a different formulation.
How should someone in Alpharetta evaluate the option?
Ask the clinician to identify the anatomical problem, exact product, regulatory status, intended layer, session plan, expected timeline, maintenance burden, and approach to delayed reactions. Ask what less treatment would look like—and what no treatment would preserve.
Natural-looking results are not created by applying a fashionable map carefully. They come from deciding whether that map belongs on this face at all.
Frequently Asked Questions
What is PDLLA?
PDLLA is poly-D,L-lactic acid, a material used in certain biostimulatory products. Formulations and authorizations vary, so the exact product matters.
Is a PDLLA biostimulator the same as hyaluronic-acid filler?
No. Mechanism, timing, reversibility, session planning, and complication management can differ substantially.
How many sessions did the new cheek study use?
Participants received three sessions at three-week intervals. That protocol should not be assumed appropriate for every product or patient.
Was the new study randomized?
No. It was an uncontrolled 24-person case series with short follow-up, so it is early evidence.
Can biostimulators be dissolved?
Do not assume the reversibility of hyaluronic-acid filler. Correction options depend on the exact product and problem.
Who may not be a good candidate?
Someone with unexplained swelling, poorly documented prior product, anatomy prone to heaviness, unrealistic reversibility expectations, or a concern not caused by volume loss may be better served by another plan or no treatment.
Evidence reviewed
PDLLA lateral-cheek case series. PubMed PMID 42640663.
Follow Dr. Lazuk
About the author
Dr. Iryna Lazuk is a physician and the founder of Lazuk Esthetics in Alpharetta, Georgia. Her work centers on individualized assessment, restraint, natural-looking outcomes, and long-term skin health.
Lazuk Esthetics | 4380 Kimball Bridge Rd, Alpharetta, GA 30022 | Concierge Service: (770) 744-3146
Medical disclaimer: This article is educational, does not endorse a specific product, and does not replace an in-person anatomical assessment or review of product-specific risks and authorization.
Comments